KR100694752B1 - 말초형 벤조디아제핀 수용체의 기능 장애와 연관된 질병치료용 의약을 제조하기 위한피리다지노[4,5-ｂ]인돌-1-아세트아미드 유도체의 용도 - Google Patents

말초형 벤조디아제핀 수용체의 기능 장애와 연관된 질병치료용 의약을 제조하기 위한피리다지노[4,5-ｂ]인돌-1-아세트아미드 유도체의 용도 Download PDF

Info

Publication number
KR100694752B1
KR100694752B1 KR1020017009272A KR20017009272A KR100694752B1 KR 100694752 B1 KR100694752 B1 KR 100694752B1 KR 1020017009272 A KR1020017009272 A KR 1020017009272A KR 20017009272 A KR20017009272 A KR 20017009272A KR 100694752 B1 KR100694752 B1 KR 100694752B1
Authority
KR
South Korea
Prior art keywords
formula
compound
atom
indole
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017009272A
Other languages
English (en)
Korean (ko)
Other versions
KR20010089624A (ko
Inventor
바디아 페르자즈
제수 베나비데
프랑 마르구에
자크 프로상
베노 마라부
야니크 에바노
미렐 세브리
필립 자니크
Original Assignee
사노피-아벤티스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피-아벤티스 filed Critical 사노피-아벤티스
Publication of KR20010089624A publication Critical patent/KR20010089624A/ko
Application granted granted Critical
Publication of KR100694752B1 publication Critical patent/KR100694752B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020017009272A 1999-01-26 2000-01-21 말초형 벤조디아제핀 수용체의 기능 장애와 연관된 질병치료용 의약을 제조하기 위한피리다지노[4,5-ｂ]인돌-1-아세트아미드 유도체의 용도 Expired - Fee Related KR100694752B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9900806A FR2788696B1 (fr) 1999-01-26 1999-01-26 Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR99/00,806 1999-01-26

Publications (2)

Publication Number Publication Date
KR20010089624A KR20010089624A (ko) 2001-10-06
KR100694752B1 true KR100694752B1 (ko) 2007-03-14

Family

ID=9541212

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017009272A Expired - Fee Related KR100694752B1 (ko) 1999-01-26 2000-01-21 말초형 벤조디아제핀 수용체의 기능 장애와 연관된 질병치료용 의약을 제조하기 위한피리다지노[4,5-ｂ]인돌-1-아세트아미드 유도체의 용도

Country Status (32)

Country Link
US (1) US6395729B1 (https=)
EP (1) EP1148881B1 (https=)
JP (1) JP4688295B2 (https=)
KR (1) KR100694752B1 (https=)
CN (1) CN100577167C (https=)
AR (1) AR022413A1 (https=)
AT (1) ATE335487T1 (https=)
AU (1) AU764445B2 (https=)
BG (1) BG65152B1 (https=)
BR (1) BR0007718A (https=)
CA (1) CA2360754C (https=)
CO (1) CO5160242A1 (https=)
CY (1) CY1106257T1 (https=)
CZ (1) CZ294283B6 (https=)
DE (1) DE60029929T2 (https=)
DK (1) DK1148881T3 (https=)
EE (1) EE04905B1 (https=)
ES (1) ES2269097T3 (https=)
FR (1) FR2788696B1 (https=)
HK (1) HK1040905B (https=)
HU (1) HU228670B1 (https=)
IL (2) IL144181A0 (https=)
NO (1) NO321997B1 (https=)
NZ (1) NZ512981A (https=)
PL (1) PL193420B1 (https=)
PT (1) PT1148881E (https=)
RU (1) RU2243764C2 (https=)
SK (1) SK285707B6 (https=)
TR (1) TR200102134T2 (https=)
TW (1) TW541177B (https=)
UA (1) UA70349C2 (https=)
WO (1) WO2000044384A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1329493A (zh) * 1998-12-02 2002-01-02 辉瑞产品公司 恢复p53家族蛋白质的构象稳定性的方法和组合物
FR2811897A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1- ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES DYSFONCTIONNEMENTS DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
FR2838124B1 (fr) 2002-04-03 2004-05-28 Sanofi Synthelabo Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique
FR2876715B1 (fr) 2004-10-19 2006-12-15 Profiles Du Ct Sa Embout de protection pour ecran de glissiere de securite routiere
GT200600005A (es) * 2005-01-12 2006-08-16 Un derivado de 2-(aminocarbonilo ciclico)-indolina y una composicion farmaceutica que lo contiene
CN101252914B (zh) * 2005-05-05 2013-03-27 塞诺菲-安万特美国有限责任公司 稳定的纳米粒制剂
BRPI0615259A2 (pt) * 2005-08-29 2011-05-17 Sanofi Aventis Us Llc forma cristalina de um derivado de piridazino[4,5-b] indol
CN101272767B (zh) * 2005-08-29 2012-08-29 赛诺菲-安万特美国有限责任公司 7-氯-N,N,5-三甲基-4-氧-3-苯基-3,5-二氢-4H-哒嗪并[4,5-b]吲哚-1-乙酰胺的无定形固体分散体
CN1946120B (zh) * 2006-10-20 2010-05-12 华为技术有限公司 实现话单关联的方法及系统
FR2918563B1 (fr) 2007-07-12 2009-12-04 Oreal Composition photoprotectrice fluide aqueuse a base d'un polymere polyamide a terminaison amide tertiaire.
FR2931064B1 (fr) 2008-05-14 2010-08-13 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un derive de pyrrolidinone; procede de photostabilisation du derive de dibenzoylmethane
CA2734448A1 (en) * 2008-08-18 2010-02-25 Sanofi-Aventis U.S. Llc Process for preparing polymorph of 7-chloro-n, n,5-trimethyl-4-oxo-3-phenyl-3,5-dihydr0-4h-pyridazin0[4,5-b]indole-1-acetamide
GB0818738D0 (en) * 2008-10-13 2008-11-19 Ge Healthcare Ltd Imaging neuroflammation
FR2936706B1 (fr) 2008-10-08 2010-12-17 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un compose dithiolane ; procede de photostabilisation du derive de dibenzoylmethane
EP2181717A1 (en) * 2008-10-28 2010-05-05 Sanofi-Aventis Use of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-B]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels
WO2011073279A2 (fr) 2009-12-18 2011-06-23 L'oreal Procédé de traitement cosmétique impliquant un composé apte à condenser in situ
FR2960773B1 (fr) 2010-06-03 2015-12-11 Oreal Procedes de traitement cosmetique utilisant un revetement a base d'un polymere polyamide-polyether
WO2019113248A1 (en) * 2017-12-07 2019-06-13 The Regents Of The University Of California Anti-upar antibody-drug conjugates and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121137A1 (de) * 1981-05-27 1982-12-16 Hoechst Ag, 6000 Frankfurt Neue pyridazino(4,5-b)indole, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen, zwischenprodukte und deren herstellung"
GB2290292A (en) * 1994-06-15 1995-12-20 Merck Sharp & Dohme 2-Phenylpyridazino[4,5-b]indole-1,4-dione derivatives as NMDA and AMPA antagonists
WO1998015552A1 (fr) * 1996-10-08 1998-04-16 Synthelabo DERIVES DE 1H-PYRIDO[3,4-b]INDOLE-4-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069267A (en) * 1997-07-29 2000-05-30 E. I. Du Pont De Nemours And Company Selective synthesis of organodiphosphite compounds
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788776B1 (fr) * 1999-01-26 2001-02-23 Synthelabo Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121137A1 (de) * 1981-05-27 1982-12-16 Hoechst Ag, 6000 Frankfurt Neue pyridazino(4,5-b)indole, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen, zwischenprodukte und deren herstellung"
GB2290292A (en) * 1994-06-15 1995-12-20 Merck Sharp & Dohme 2-Phenylpyridazino[4,5-b]indole-1,4-dione derivatives as NMDA and AMPA antagonists
WO1998015552A1 (fr) * 1996-10-08 1998-04-16 Synthelabo DERIVES DE 1H-PYRIDO[3,4-b]INDOLE-4-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Also Published As

Publication number Publication date
UA70349C2 (en) 2004-10-15
FR2788696B1 (fr) 2004-03-05
WO2000044384A1 (fr) 2000-08-03
ATE335487T1 (de) 2006-09-15
CA2360754A1 (en) 2000-08-03
TW541177B (en) 2003-07-11
DE60029929D1 (de) 2006-09-21
CN1344161A (zh) 2002-04-10
CZ20012681A3 (cs) 2001-10-17
DE60029929T2 (de) 2007-08-30
HUP0201280A3 (en) 2004-12-28
CA2360754C (en) 2008-07-08
CN100577167C (zh) 2010-01-06
CY1106257T1 (el) 2011-06-08
PT1148881E (pt) 2006-12-29
KR20010089624A (ko) 2001-10-06
EE200100388A (et) 2002-12-16
NO321997B1 (no) 2006-07-31
PL349364A1 (en) 2002-07-15
AR022413A1 (es) 2002-09-04
DK1148881T3 (da) 2006-12-11
ES2269097T3 (es) 2007-04-01
NO20013645L (no) 2001-09-26
CO5160242A1 (es) 2002-05-30
EE04905B1 (et) 2007-10-15
SK10502001A3 (sk) 2002-01-07
BG105728A (en) 2002-02-28
PL193420B1 (pl) 2007-02-28
HUP0201280A2 (en) 2002-08-28
JP4688295B2 (ja) 2011-05-25
CZ294283B6 (cs) 2004-11-10
EP1148881A1 (fr) 2001-10-31
AU3057900A (en) 2000-08-18
TR200102134T2 (tr) 2003-03-21
HK1040905A1 (en) 2002-06-28
JP2002535370A (ja) 2002-10-22
HU228670B1 (en) 2013-05-28
IL144181A0 (en) 2002-05-23
RU2243764C2 (ru) 2005-01-10
NO20013645D0 (no) 2001-07-24
EP1148881B1 (fr) 2006-08-09
AU764445B2 (en) 2003-08-21
FR2788696A1 (fr) 2000-07-28
BG65152B1 (bg) 2007-04-30
US6395729B1 (en) 2002-05-28
NZ512981A (en) 2002-10-25
IL144181A (en) 2007-06-17
HK1040905B (zh) 2007-02-23
BR0007718A (pt) 2001-11-13
SK285707B6 (sk) 2007-06-07

Similar Documents

Publication Publication Date Title
KR100694752B1 (ko) 말초형 벤조디아제핀 수용체의 기능 장애와 연관된 질병치료용 의약을 제조하기 위한피리다지노[4,5-ｂ]인돌-1-아세트아미드 유도체의 용도
WO2020177292A1 (zh) Rock抑制剂-二氯乙酸复盐及其制备方法和用途
EP1244670B1 (en) Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
AU1841300A (en) Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds
CN113698345B (zh) 作为钾通道调节剂的化合物及其制备和应用
EP0512817B1 (en) Pyridazinedione derivatives, their preparation and pharmaceutical applications
US9932352B2 (en) Compounds for the treatment of ischemia-reperfusion-related diseases
WO2002007727A1 (fr) Utilisation de derives de pyridazino (4, 5) indole-1-acetamide pour la preparation de medicaments destines au traitement des pathologies liees aux dysfonctionnements des recepteurs de type peripherique aux benzodiazepines
MXPA01007550A (en) USE OF PYRIDAZINO[4,5-b
KR20040094904A (ko) 3-헤테로아릴-3,5-디히드로-4-옥소-4Ｈ-피리다지노[4,5-ｂ]인돌-1-아세트아미드 유도체, 그의 제조 방법 및의약에서의 그의 용도
HK40058596B (en) Compounds as potassium channel regulators and preparation and use thereof
HK40058596A (zh) 作为钾通道调节剂的化合物及其制备和应用
JPWO2003087091A1 (ja) キノキサリンジオン誘導体無水物の新規結晶

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20120221

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20130221

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140308

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140308

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000